Business Wire

ALLEGRO-DVT

14.12.2022 15:01:44 CET | Business Wire | Press release

Share
Labwise by Allegro DVT Introduces StreamWise-ATSC Test Suites to Accelerate Conformance Testing of ATSC 3.0 Receivers

Labwise the leader in digital TV conformance testing announces the availability of StreamWise-ATSC its latest digital TV test suites that enable testing of ATSC 3.0 (NEXTGEN TV) receivers and TV sets to ensure their conformance with ATSC 3.0 TV service features.

Labwise, a recognized leader in digital TV device testing services, was acquired by Allegro DVT, the worldwide leader in video codec compliance streams, in June 2022. Labwise has been operating as an independent, impartial, and objective testing house since 2004, providing professional digital TV test suites and services to major TV OEMs, digital TV broadcasters and operators across Europe.

Anne Schelle, Managing Director of Pearl TV commented “ATSC 3.0 brings many new broadcast TV features through multiple advanced technologies to enhance the user viewing experience. The industry needs to ensure that devices are interoperable and properly implement the ATSC 3.0 features though trusted conformance testing. We welcome this announcement from Labwise, as an established and trusted player in digital TV testing which will further accelerate the adoption of NEXTGEN TV across the USA and other markets.”

Nouar Hamze, CEO of Allegro DVT added " Today’s launch of StreamWise-ATSC is at the heart of our new strategy to extend our Digital TV testing products to cover ATSC 3.0. Labwise, the latest addition of Allegro DVT group of companies, has gained tremendous expertise and become a trusted and impartial test house in multiple markets across Europe. The entire ATSC 3.0 ecosystem including device manufacturers and broadcasters, will benefit from StreamWise-ATSC by having access to feature-rich, reliable and trusted test suites."

StreamWise-ATSC by Labwise enables the testing of NEXTGEN TV broadcast service profile. These test suites allow device manufacturers to verify the compliance of products, or have devices tested as a service at Labwise laboratory to cover all the features and help tackle the technological complexity brought by the ATSC 3.0 standard.

The laboratory test environment is targeted for the device black box testing and is provided with optional HW environment for broadcast modulation. The test system includes the ATSC 3.0 test plan and the test case information i.e., test configuration, procedures, and specification references to make it easy for the tests engineer to perform the tests. The test streams are provided in playout formats (ROUTE/DASH and MMT).

More precisely these test suites cover multiple features such as:

Video

  • Resolutions and Frame rates
  • Legacy SD Video
  • SDR
  • HDR – PQ/HLG, WCG
  • HFR
  • AFD
  • Metadata Messages

Subtitles and captions

  • Language, role, etc support
  • Formats, areas etc.

Audio

  • Formats and sampling rates
  • Immersive
  • Downscaling
  • Audio track selection
  • Receiver output – HDMI/ARC, SP/DIF, analog
  • Multilanguage
  • AD and other special tracks

Delivery

 

  • Signalling
  • Discovery etc.

Advanced Emergency Alerting

About Pearl TV

Pearl TV is a business organization of U.S. broadcast companies with a shared interest in exploring forward-looking broadcasting opportunities, including innovative ways of promoting local broadcast TV content and developing digital media and wireless platforms for the broadcast industry. Pearl’s membership, comprising more than 820 TV stations, includes eight of the largest broadcast companies in America: Cox Media Group, Graham Media Group, Gray Television, Hearst Television Inc., Nexstar Media Group, Sinclair Broadcast Group, the E.W. Scripps Company, and TEGNA Inc.

About Allegro DVT

Allegro DVT is a world leading provider of digital video technology solutions including compliance streams. Labwise operates as an independent, impartial, and objective testing house providing professional digital TV test services to major TV OEMs, digital TV broadcasters and operator across Europe.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005107/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release

Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP

Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release

Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp

KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release

Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen

Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR

Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye